VISION

Insights IAS Monthly Editorial Magazine October 2022 PDF

Insights IAS Editorial January 2022 PDF

Insights IAS Editorial November 2021 PDF

 Insights IAS Editorial August 2021 PDF

Insights IAS Editorial July 2021 PDF 

 Insights IAS Editorial June 2021 PDF

 Insights IAS Editorial May 2021 PDF

 What is the issue?

• The Government of India unveiled a completely revamped vaccine strategy.
• The resultant vaccine inequity could make containment measures more difficult.

What is the recent decision?

• Two key elements are the hallmark of this new strategy, which will be implemented from May 1, 2021.
• 1) The phased roll-out of the vaccination drive (initiated on January 16, 2021), under which the vaccine-eligible sections of the population were gradually increased, has now been extended to the entire adult population.
• All above 18 years will now get vaccinated.
• 2) A significant deregulation of the vaccine market has been effected.
• Vaccine manufacturers now have the freedom to sell 50% of their vaccine production to State governments and private hospitals.
• This can be sold at prices that can be substantially higher than that hitherto fixed by the government.
• A third element of the vaccine strategy, which was not announced formally, is a grant of ₹45 billion to the two vaccine manufacturers to boost their capacities.
  • Serum Institute of India (SII) and Bharat Biotech.

What are the concerns?

 Insights IAS Editorial February 2021 PDF